Search Result

Results for "

tau hyperphosphorylation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Tau Protein (21) 17β-HSD (1) Akt (2) Amyloid-β (7) Apoptosis (9) Bcl-2 Family (1) Beta-secretase (1) CaMK (1) CDK (2) Cholinesterase (ChE) (5) Drug Derivative (1) DYRK (2) ERK (1) Ferroptosis (1) FGFR (2) Glucocorticoid Receptor (4) GLUT (1) GSK-3 (12) HDAC (1) Histamine Receptor (1) HSV (2) iGluR (4) IKK (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (2) Isotope-Labeled Compounds (2) JNK (3) MEK (1) Microtubule/Tubulin (1) Mineralocorticoid Receptor (4) Mitochondrial Metabolism (1) Mixed Lineage Kinase (1) mTOR (5) NF-κB (3) NOD-like Receptor (NLR) (2) p38 MAPK (1) Phospholipase (1) PI3K (2) PKC (1) Potassium Channel (2) PROTACs (1) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) RIP kinase (2) Src (1) TNF Receptor (3) TRP Channel (2) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (7) Infection (2) Inflammation/Immunology (14) Metabolic Disease (9) Neurological Disease (29)

By Targets:

Tau Protein (21)

17β-HSD (1)

Akt (2)

Amyloid-β (7)

Apoptosis (9)

Bcl-2 Family (1)

Beta-secretase (1)

CaMK (1)

CDK (2)

Cholinesterase (ChE) (5)

Drug Derivative (1)

DYRK (2)

ERK (1)

Ferroptosis (1)

FGFR (2)

Glucocorticoid Receptor (4)

GLUT (1)

GSK-3 (12)

HDAC (1)

Histamine Receptor (1)

HSV (2)

iGluR (4)

IKK (2)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

JNK (3)

MEK (1)

Microtubule/Tubulin (1)

Mineralocorticoid Receptor (4)

Mitochondrial Metabolism (1)

Mixed Lineage Kinase (1)

mTOR (5)

NF-κB (3)

NOD-like Receptor (NLR) (2)

p38 MAPK (1)

Phospholipase (1)

PI3K (2)

PKC (1)

Potassium Channel (2)

PROTACs (1)

Proteasome (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

RIP kinase (2)

Src (1)

TNF Receptor (3)

TRP Channel (2)

Wnt (1)

β-catenin (2)

By Research Areas:

Cancer (7)

Infection (2)

Inflammation/Immunology (14)

Metabolic Disease (9)

Neurological Disease (29)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Tau Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1203

Fludrocortisone 9α-Fludrocortisone; 9α-Fluorcortisol	Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone (9α-Fludrocortisone) is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks *Tau* hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency .

HY-122704A

Surfen dihydrochloride 2 Publications Verification Aminoquinuride dihydrochloride	FGFR HSV Tau Protein	Infection Neurological Disease Inflammation/Immunology
Surfen dihydrochloride is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces *tau* hyperphosphorylation. Surfen dihydrochloride inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC₅₀ of approximately 2 μM. Surfen dihydrochloride inhibits HSV-1 viral infection. Surfen dihydrochloride inhibits neural differentiation, delays remyelination, and alleviates EAE .

HY-148907

CS640	CaMK MEK Mixed Lineage Kinase RIP kinase Tau Protein	Neurological Disease
CS640 (Compound 19) is a chemical probe and a calmodulin-dependent kinase inhibitor. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, MEK5, RIPK4, mLK3 and PIP5K1, with IC₅₀ values of 8, 3, 1, 1, 25 nM, 5.69, 2.75 and 11.2 μM, respectively. CS640 blocks Aβ-induced hyperphosphorylation of *tau* protein at the Thr181 site, but fails to protect primary mouse cortical neurons from Aβ-induced toxic damage. CS640 is applicable to research related to Alzheimer's disease .

HY-139142

Simufilam 1 Publications Verification PTI-125	mTOR iGluR Amyloid-β Tau Protein	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and *tau* protein hyperphosphorylation. Simufilam can be used for research of Alzheimer's disease .

HY-153166

PT-65	PROTACs GSK-3 Tau Protein	Neurological Disease
PT-65 is a GSK3α and GSK3β PROTAC degrader with DC₅₀ values of 28.3 nM and 34.2 nM, respectively. PT-65 inhibits excessive tau phosphorylation mediated by GSK3β, Aβ and Okadaic acid (HY-N6785). PT-65 is applicable for the research of Alzheimer's disease .

HY-N0695

Schisantherin B 1 Publications Verification Gomisin-B; Wuweizi ester-B; Schisantherin-B	PI3K Akt mTOR GSK-3 Tau Protein TNF Receptor Interleukin Related Apoptosis	Neurological Disease Inflammation/Immunology
Schisantherin B (Gomisin-B) is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of *tau* protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression .

HY-139066

Punicic acid 1 Publications Verification Trichosanic acid	TNF Receptor GLUT Proteasome Tau Protein PKC	Neurological Disease Metabolic Disease Inflammation/Immunology
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .

HY-B1239

Drofenine hydrochloride 1 Publications Verification Hexahydroadiphenine hydrochloride	Cholinesterase (ChE) Potassium Channel Amyloid-β TRP Channel Tau Protein NOD-like Receptor (NLR) JNK NF-κB IKK	Neurological Disease Metabolic Disease Inflammation/Immunology
Drofenine (Cycloadiphene; Hexahydroadiphenine) hydrochloride is an brain-penetrant antispasmodic agent. Drofenine hydrochloride is a Kv2.1 channel inhibitor with human IC₅₀ of 9.53 μM. Drofenine hydrochloride is a butyrylcholinesterase (BChE) inhibitor with K_i of 0.003 mM, and is a TRPV3 activator. Drofenine hydrochloride blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal *Tau* hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine hydrochloride induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine hydrochloride ameliorates diabetic peripheral neuropathy -like pathology. Drofenine hydrochloride can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm .

HY-144290

ARN25068	GSK-3 DYRK	Neurological Disease
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

HY-121035

7BIO 7-Bromoindirubin-3-Oxime	CDK GSK-3	Neurological Disease
7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice ^[1].

HY-139142B

Simufilam hydrochloride 1 Publications Verification PTI-125 hydrochloride	mTOR iGluR Amyloid-β Tau Protein	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Simufilam hydrochloride (PTI-125 hydrochloride) is an orally active FLNA modulator. Simufilam hydrochloride restores NMDAR signaling and Arc expression. Simufilam hydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and *tau* protein hyperphosphorylation. Simufilam hydrochloride can be used for research of Alzheimer's disease .

HY-173371

BRI-50460	Phospholipase	Neurological Disease
BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) that has the ability to penetrate the blood-brain barrier, with an IC₅₀ of 0.88 nM. BRI-50460 exerts the activities of regulating neuroinflammation and restoring lipid homeostasis by inhibiting cPLA2, regulating the downstream inflammatory lipid signaling pathway, and alleviating the effects of amyloid β42 oligomers on the activation of cPLA2, the hyperphosphorylation of *tau* protein, and the reduction of synapses and dendrites. BRI-50460 can be applied to the research in the fields of Alzheimer's disease and other neurodegenerative diseases .

HY-151873

SZM679	RIP kinase	Inflammation/Immunology Cancer
SZM679 is a potent, orally active and selective RIPK1 inhibitor with K_d values of 8.6 nM and >5000 nM for RIPK1 and RIPK3, respectively. SZM679 reverses the tumor necrosis factor-induced systemic inflammatory response. SZM679 decreases the Tau hyperphosphorylation, neuroinflammation, and the RIPK1 phosphorylation level in the hippocampus and cortex. SZM679 can be used in research of Alzheimer's disease (AD) .

HY-172171

GSK3β-IN-2	GSK-3 β-catenin Wnt	Neurological Disease
GSK3β-IN-2 (Compound S01) is the inhibitor for GSK3β with an IC₅₀ of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model .

HY-139142A

Simufilam dihydrochloride PTI-125 dihydrochloride	Tau Protein Amyloid-β mTOR iGluR	Neurological Disease
Simufilam dihydrochloride (PTI-125 dihydrochloride) is an orally active FLNA modulator. Simufilam dihydrochloride restores NMDAR signaling and Arc expression. Simufilam dihydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and *tau* protein hyperphosphorylation. Simufilam dihydrochloride can be used for research of Alzheimer's disease .

HY-122704

Surfen Aminoquinuride	FGFR HSV Tau Protein	Infection Neurological Disease Inflammation/Immunology
Surfen is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces *tau* hyperphosphorylation. Surfen inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC₅₀ of approximately 2 μM. Surfen inhibits HSV-1 viral infection. Surfen inhibits neural differentiation, delays remyelination, and alleviates EAE .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-168857

GSK-3β inhibitor 24	GSK-3 Tau Protein β-catenin	Neurological Disease
GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC₅₀ of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of *tau* protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .

HY-174398

GSK-3β/HDAC-IN-2	GSK-3 HDAC Tau Protein	Neurological Disease
GSK-3β/HDAC-IN-2 is a potent inhibitor of GSK-3β (IC₅₀ = 0.04 μM), HDAC2 (IC₅₀ = 1.05 μM, Ki = 0.070 μM) and HDAC6 (IC₅₀ = 1.52 μM, Ki = 0.017 μM). GSK-3β/HDAC-IN-2 inhibits HDAC2 and HDAC6 activities and blocks tau hyperphosphorylation. GSK-3β/HDAC-IN-2 exerts neuroprotective effects and shows no significant toxicity. GSK-3β/HDAC-IN-2 can be used in the research of Alzheimer's disease.

HY-174272

GSK-3β inhibitor 27	GSK-3 Amyloid-β	Neurological Disease
GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC₅₀ value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .

HY-175841

*Tau Protein Phosphorylation-IN-1*	Tau Protein p38 MAPK NF-κB Apoptosis Bcl-2 Family ERK JNK	Neurological Disease
Tau Protein Phosphorylation-IN-1 is a tau protein phosphorylation inhibitor that potently protects PC12 cells against Aβ_25–35-induced cytotoxicity (EC₅₀ = 1.93 μM), and can penetrate the blood-brain barrier (BBB).Tau Protein Phosphorylation-IN-1 reverses the hyperphosphorylation of tau, significantly inhibits the expression of certain immune-related cytotoxic factors, suppresses the MAPK and NF-κB signaling pathways, and significantly inhibits the expression of RAGE and the apoptosis factors Bax/Bcl-2, both in vitro and in vivo. Tau Protein Phosphorylation-IN-1 relieves nerve damage, and improves learning and memory in an Alzheimer’s disease (AD) mouse model. Tau Protein Phosphorylation-IN-1 can be used for AD research .

HY-B1239A

Drofenine Cycloadiphene; Hexahydroadiphenine	Potassium Channel Cholinesterase (ChE) TRP Channel NOD-like Receptor (NLR) Amyloid-β Tau Protein JNK NF-κB IKK	Neurological Disease Metabolic Disease Inflammation/Immunology
Drofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC₅₀ of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with K_i of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal *Tau* hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm .

HY-170389

BChE-IN-39	Cholinesterase (ChE)	Neurological Disease
BChE-IN-39 (Compound 7c) is a selective inhibitor for butyrylcholinesterase (BChE) with an IC₅₀ of 0.08 μM (IC₅₀=3.98 μM for AChE). BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein .

HY-172176

RA-PR058	Beta-secretase Tau Protein	Neurological Disease
RA-PR058 is an orally active Ramalin derivative with blood-brain barrier permeability, exhibiting multi-target regulatory effects and favorable pharmacokinetic properties. RA-PR058 demonstrates potential as a multi-target modulator for Alzheimer's disease by reducing the expression of BACE1, tau protein hyperphosphorylation, and anxiety-like behaviors .

HY-144316

ZLWH-23	Cholinesterase (ChE) GSK-3	Neurological Disease
ZLWH-23 is a selective AChE inhibitor (IC₅₀=0.27 μM) with GSK-3β inhibitory property (IC₅₀=6.78 μM). ZLWH-23 possesses selectivity for AChE over BChE (IC₅₀=20.82 μM) and for GSK-3β over multi-kinases. ZLWH-23 has the potential for the research of Alzheimer's disease .

HY-N0695R

Schisantherin B (Standard) Gomisin-B (Standard); Wuweizi ester-B (Standard); Schisantherin-B (Standard)	Reference Standards PI3K Akt mTOR GSK-3 Tau Protein TNF Receptor Interleukin Related Apoptosis	Neurological Disease Inflammation/Immunology
Schisantherin B (Gomisin-B) (Standard) is the analytical standard of Schisantherin B. This product is intended for research and analytical applications. Schisantherin B is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of *tau* protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression.

HY-B1203S

Fludrocortisone-d5 9α-Fludrocortisone-d₅; 9α-Fluorcortisol-d₅	Isotope-Labeled Compounds Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks *Tau* hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203R

Fludrocortisone (Standard) 9α-Fludrocortisone (Standard); 9α-Fluorcortisol (Standard)	Reference Standards Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone (Standard) (9α-Fludrocortisone (Standard)) is the analytical standard of Fludrocortisone (HY-B1203). This product is intended for research and analytical applications. Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks *Tau* hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203S1

Fludrocortisone-d2 9α-Fludrocortisone-d₂; 9α-Fluorcortisol-d₂	Isotope-Labeled Compounds Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks *Tau* hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-162812

H3R antagonist 4	Apoptosis Cholinesterase (ChE) Tau Protein Ferroptosis Histamine Receptor	Neurological Disease
H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC₅₀ of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ_1-42 induced by itself and Cu ²⁺ (95.48% and 88.63%) , and degraded the Aβ_1-42 fibrils induced by itself and Cu ²⁺ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu ²⁺, Zn ²⁺, Al ³⁺, and Fe ²⁺. H3R antagonist 4 significantly reduced *tau* protein hyperphosphorylation induced by Aβ_1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .

HY-184078

8-F-2-(Me-Pip-Me)-Tryptanthrin	Drug Derivative Indoleamine 2,3-Dioxygenase (IDO) Tau Protein iGluR	Neurological Disease
8-F-2-(Me-Pip-Me)-Tryptanthrin is a tryptanthrin derivative with blood-brain barrier penetration. 8-F-2-(Me-Pip-Me)-Tryptanthrin protects neurons from Aβ-induced apoptosis, inhibits Aβ-induced *Tau* protein hyperphosphorylation and neuronal synaptic damage, and improves learning and memory abilities in Alzheimer's disease mice. 8-F-2-(Me-Pip-Me)-Tryptanthrin can be used for the research of nervous system diseases, including diseases related to abnormal *Tau* protein phosphorylation and abnormal PSD-95 function .

HY-183584

ARN25699	GSK-3 Src DYRK Tau Protein Microtubule/Tubulin	Neurological Disease
ARN25699 is a kinase inhibitor with an IC₅₀ of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies .

HY-182028

17β-HSD10-IN-4	17β-HSD Reactive Oxygen Species (ROS) Tau Protein Amyloid-β CDK Mitochondrial Metabolism	Neurological Disease
17β-HSD10-IN-4 is a selective brain-penetrant 17β-HSD10 inhibitor with an IC₅₀ of 6.33 μM. 17β-HSD10-IN-4 forms key interactions with the 17β-HSD10 catalytic triad to functionally inhibit the enzyme, without altering its protein levels. 17β-HSD10-IN-4 restores mitochondrial function, reduces ROS levels, increases ATP production, and suppresses cytochrome c release. 17β-HSD10-IN-4 attenuates CDK5/p25 activation, reduces *Tau* hyperphosphorylation, Aβ plaque load and restores brain-derived neurotrophic factor levels. 17β-HSD10-IN-4 improves cognitive function.17β-HSD10-IN-4 can be used for the research of Alzheimer's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0695

Schisantherin B 1 Publications Verification Gomisin-B; Wuweizi ester-B; Schisantherin-B	Structural Classification Classification of Application Fields Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Inflammation/Immunology Disease Research Fields Source Classification	PI3K Akt mTOR GSK-3 Tau Protein TNF Receptor Interleukin Related Apoptosis
Schisantherin B (Gomisin-B) is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of *tau* protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression .

HY-139066

Punicic acid 1 Publications Verification Trichosanic acid	Structural Classification Punica granatum L. Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Punicaceae Plants Disease Research Fields Source Classification	TNF Receptor GLUT Proteasome Tau Protein PKC
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .

HY-N0695R

Schisantherin B (Standard) Gomisin-B (Standard); Wuweizi ester-B (Standard); Schisantherin-B (Standard)	Structural Classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Source Classification	Reference Standards PI3K Akt mTOR GSK-3 Tau Protein TNF Receptor Interleukin Related Apoptosis
Schisantherin B (Gomisin-B) (Standard) is the analytical standard of Schisantherin B. This product is intended for research and analytical applications. Schisantherin B is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of *tau* protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression.

Cat. No.	Product Name	Chemical Structure

HY-B1203S

Fludrocortisone-d5
Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks *Tau* hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Fludrocortisone-d5

Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203S1

Fludrocortisone-d2
Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks *Tau* hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Fludrocortisone-d2

Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks